apixaban + placebo

This entry refers to the combination of apixaban, an oral anticoagulant, and placebo as used in clinical trials. Apixaban is a direct factor Xa inhibitor that prevents blood clot formation by selectively blocking the activity of factor Xa, a key enzyme in the coagulation cascade. It is primarily indicated for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for reducing stroke risk in patients with nonvalvular atrial fibrillation[1][2][4][5]. Placebo is an inert substance with no pharmacological effect, used as a control in clinical studies to assess the efficacy and safety of active drugs such as apixaban[7]. The combination "apixaban + placebo" does not represent a marketed pharmaceutical product but rather denotes arms or groups within randomized controlled trials where one group receives apixaban and another receives placebo.

Other names

Placebo